TORRENT PHARMACEUTICALS LTD
QTRLY RESULTS FOR Q1 FY 2014-15
(JUNE 2014)
TORRENT
PHARMA has produced excellent Results for the first quarter ending June,2014.
|
Torrent Pharma
|
Q1 FY15
|
Q1 FY14
|
Growth
|
FY 14
|
FY13
|
Growth
|
|
Revenues
|
1114
|
972
|
15%
|
4184
|
3212
|
30%
|
|
EBITDA
|
345
|
208
|
66%
|
952
|
693
|
37%
|
|
% of Revenues
|
31%
|
21%
|
23%
|
22%
|
||
|
PBT
|
349
|
187
|
87%
|
844
|
582
|
45%
|
|
PAT
|
256
|
149
|
72%
|
664
|
435
|
53%
|
|
%Revenues
|
23%
|
15%
|
16%
|
14%
|
||
|
EPS-FV Rs.5
|
15.1
|
8.8
|
72%
|
39
|
26
|
53%
|
Domestic
Formulations Business recorded growth of 13% and International revenues Grew by
36%. Revenues from US operations grew by 138%.
During
the quarter, Torrent consummated acquisition of Identified Indian Branded
formulations Business of Elder Pharma for a consideration of Rs.2000 Cr.
Borrowing of Rs.1400 Cr for the deal.
|
Torrwent Pharma
|
Q1 FY 14
|
Q2FY14
|
Q3FY14
|
Q4FY14
|
Q1FY15
|
|
MKT CAP
|
6952
|
7392
|
8021
|
8860
|
1114
|
|
REVENUE
|
972
|
972
|
1015
|
1225
|
1114
|
|
PBT
|
187
|
152
|
188
|
317
|
349
|
|
PAT
|
149
|
113
|
158
|
244
|
256
|
GROWTH
DRIVERS IN INTERNATIONAL MARKETS
As of Jun‐14 the Company has 48 ANDA approvals
(including 5 tentative approvals) and its pipeline consists of 22 pending approvals
and 46 products under development.
• 8 to 10 products expected to be
launched in FY 15.
Torrent Pharma's Q1 FY 15 EPS is Rs.15.1. If this is
annualized, the annual EPS will be around Rs.60. Current Market price is around
Rs.755. So, PE Ratio works out to 12.58. We will need to watch if Torrent is
able to maintain this level of EPS and improve on it in coming Quarters.
Going forward, the acquisition of
Elder Pharma’s selected Business may prove to be a Big Growth driver for
Torrent Pharma.
* * *
E N D
* * *
No comments:
Post a Comment